This week's sponsor is ReSolution Latin America. | | | Today's Rundown Andrew Cheng to quit Gilead 6 months after taking CMO post Karuna names Lilly veteran, ex-Voyager CEO Steven Paul as leader Novocure speeds up trial of drug-device combo in pancreatic cancer [Sponsored] Rooted in Purpose: One Company’s Journey toward the First Treatment for a Rare Lung Disease Pfizer alumnus Geno Germano heads up nanoparticle startup Elucida How elephants resist cancer by reviving a ‘zombie’ gene CRO Antibody Analytics partners with online research firm Science Exchange Featured Story | Wednesday, August 15, 2018 Andrew Cheng is set to leave Gilead six months after being appointed CMO. Cheng’s swift exit keeps the revolving door spinning at the top of Gilead, which is set to lose its CEO, CMO, CSO and executive chairman over a nine-month window. |
|
| This week's sponsor is Catalent. | | Article | The Importance of Clinical Returns Planning Study sponsors often focus on upfront planning to ensure clinical sites are prepared to reach study milestones but ignore the logical challenges of managing their clinical returns. Learn how developing a forward-thinking plan to manage clinical returns can reduce study close out risk. | Top Stories Wednesday, August 15, 2018 Steven Paul, M.D., has taken over as CEO of Karuna Pharmaceuticals. The appointment puts the Sage and Voyager co-founder in charge of advancing a muscarinic agonist he worked on at Eli Lilly in the 1990s. Wednesday, August 15, 2018 Novocure has teamed up with a cancer physician network to accelerate patient recruitment in its pivotal pancreatic cancer trial, which pairs a tumor-killing device with chemotherapy. Monday, August 13, 2018 With a novel therapy under FDA review, Insmed hopes to change the treatment paradigm for patients in the U.S. suffering from a rare and debilitating lung disease. Wednesday, August 15, 2018 After a short stint at Intrexon, pharma veteran Geno Germano is taking the CEO spot at Elucida Oncology, which is developing a nanoparticle platform for diagnosing and treating cancer. Tuesday, August 14, 2018 Researchers at the University of Chicago have discovered that in elephants, the tumor-suppressor gene p53 awakens a dormant gene, which goes on to kill cancer precursor cells. They believe the discovery could be used to develop drugs that mimic this process. Wednesday, August 15, 2018 Antibody Analytics, a U.K.-based bioanalytics CRO, is teaming with Science Exchange to offer its surface plasmon resonance services to a global research community. This week's sponsor is FierceBiotech. | | | Resources Sponsored by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: PharmaCord When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients. Sponsored by: WCG Selecting the right sites is the most crucial decision you’ll make in your next clinical trial, and the single most important factor to consider in selecting a site is whether or not it can meet its enrollment goals. Sponsored by: Veeva Industry Research: See new results from one of the industry's largest, global clinical operations surveys. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BIO Latin America 2018 September 4-5, 2018 | São Paulo, Brazil RESI HealthTech Week September 5-7, 2018 | Boston, MA 4th Annual Bio/Pharmaceutical Product Launch Summit September 25-26, 2018 | Cambridge, MA Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL 2018 BIO Investor Forum October 17-18, 2018 | Westin St. Francis, San Francisco, CA FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Field Service Amsterdam November 27-28, 2018 | NH Collection Amsterdam Grand Hotel Krasnapolsky |